Grants per year
Search results
-
Active
Prot #0610-02: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients wi
Stein, B. L. (PD/PI)
Parexel, Constellation Pharmaceuticals, Inc.
10/2/18 → 10/2/24
Project: Research project
-
Finished
Prot #CPI 0610-04: A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (MANIFEST-2)
Stein, B. L. (PD/PI)
Novella Clinical, LLC, Constellation Pharmaceuticals, Inc.
7/26/21 → 7/26/24
Project: Research project
-
Targeting Plek2 for the treatment of myeloproliferative neoplasms
Ji, P. (PD/PI) & Stein, B. L. (Co-Investigator)
7/1/19 → 6/30/22
Project: Research project
-
Prot #KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
Stein, B. L. (PD/PI)
PRA Health Sciences, Kartos Therapeutics, Inc.
4/15/19 → 4/15/24
Project: Research project
-
Prot #KRT-232-102: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Stein, B. L. (PD/PI)
PRA Health Sciences, Kartos Therapeutics, Inc.
4/15/19 → 4/15/22
Project: Research project
-
Prot #INCB-MA-MF-401: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy
Stein, B. L. (PD/PI)
Syneos Health, Inc., Incyte Corporation
6/12/18 → 6/12/24
Project: Research project
-
Prot #PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Stein, B. L. (PD/PI)
PSI Pharma Support America Inc., CTI BioPharma Corp.
10/25/17 → 10/25/23
Project: Research project
-
Anti-PDL1 therapy for patients with Myelofibrosis
Stein, B. L. (PD/PI), Wainwright, D. A. (Co-Investigator) & Wolniak, K. L. (Co-Investigator)
MPN Research Foundation and the Leukemia & Lymphoma Society
8/1/16 → 5/22/17
Project: Research project
-
Prot #PAC326: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Stein, B. L. (PD/PI)
1/6/15 → 1/6/18
Project: Research project
-
MLN8237, an Aurora A kinase inhibitor, for treatment of myeloid malignancies
Crispino, J. D. (PD/PI), Altman, J. K. (Co-Investigator), Giles, F. J. (Co-Investigator), Stein, B. L. (Co-Investigator) & Wen, Q. (Other)
10/1/14 → 8/31/19
Project: Research project
-
Development of an oral anti-fibrotic drug for patients with myelofibrosis
Stein, B. L. (Co-Investigator)
10/1/13 → 9/30/16
Project: Research project
-
Prot #INCB 18424-357: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
Stein, B. L. (PD/PI)
PharmaNet, Inc., Incyte Corporation
1/17/13 → 1/17/19
Project: Research project
-
Prot #NS-018-101: A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofib
Stein, B. L. (PD/PI)
12/13/12 → 12/31/21
Project: Research project
-
Prot# NU MSK 11H01: Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Altman, J. K. (PD/PI), Frankfurt, O. (Co-PD/PI), Stein, B. L. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)
Memorial Sloan-Kettering Cancer Center
6/15/12 → 6/15/18
Project: Research project
-
Prot# INCB 18424-258: An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50x
Stein, B. L. (PD/PI)
PPD Development, Incyte Corporation
11/1/11 → 11/1/17
Project: Research project
-
Prot#CINC424B2301: Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care (The RESPONSE Trial)
Stein, B. L. (PD/PI)
9/23/11 → 9/23/17
Project: Research project
-
The Role of Tissue Factor and PAI-1 in Thrombosis and Myelofibrosis in the Myeloproliferative Neoplasms
Stein, B. L. (PD/PI)
1/1/11 → 12/31/11
Project: Research project